Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546364 | 0.85 | CYP1A2 (0.45) | CYP1A2CYP2A6KDM4EMEN1KMT2A | |
| SCHEMBL5543342 | 0.81 | CYP1A2 (0.45) | CYP1A2CYP2A6KDM4EMEN1KMT2A | |
| SCHEMBL5543995 | 0.80 | ALDH1A1 (0.47) | CYP1A2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL19382614 | 0.74 | CYP1A2 (0.61) | CYP1A2CYP2A6KDM4EMEN1KMT2A | |
| SCHEMBL5547486 | 0.72 | MTNR1A (0.47) | KDM4EMEN1KMT2AALDH1A1GFER | |
| SCHEMBL443070 | 0.71 | CYP1A2 (0.79) | CYP1A2CYP2A6KDM4EMEN1KMT2A | |
| SCHEMBL29447161 | 0.71 | CYP1A2 (0.79) | CYP1A2CYP2A6KDM4EMEN1KMT2A | |
| SCHEMBL4789564 | 0.70 | CYP1A2 (0.56) | CYP1A2CYP2A6KDM4EMEN1KMT2A | |
| SCHEMBL2094558 | 0.69 | CYP2A6 (0.42) | CYP2A6KDM4ESMN1; SMN2CA2 | |
| SCHEMBL5546370 | 0.69 | CYP1A2 (0.45) | CYP1A2CYP2A6KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281456-A1 | NOVEL BICYCLIC COMPOUNDS | PRISM BioLab Co., Ltd. (JP) | 2023-11-29 | — | — | EP | disclosed |
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| WO-2023200017-A1 | NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-10-19 | — | — | WO | disclosed |
| CN-116710455-A | Novel bicyclic compounds | 株式会社棱镜生物实验室 | 2023-09-05 | — | — | CN | disclosed |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-4225760-A1 | NOVEL BICYCLIC COMPOUNDS | PRISM BioLab Co., Ltd. (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-116348119-A | Novel bicyclic compounds | 株式会社棱镜生物实验室 | 2023-06-27 | — | — | CN | disclosed |
| EP-4182317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PRISM BioLab Co., Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
| CN-116018345-A | Novel heterocyclic compounds | 株式会社棱镜生物实验室 | 2023-04-25 | — | — | CN | disclosed |
| WO-2022075486-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2022-04-14 | — | — | WO | disclosed |
| CN-106458904-B | N-substituted sulfonamide compound and process for producing the same | 宇部兴产株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-10774072-B2 | Crystal of N-substituted sulfonamide compound | UBE INDUSTRIES, LTD. (JP) | 2020-09-15 | — | — | US | disclosed |
| US-10428046-B2 | N-substituted sulfonamide compound and method for producing same | UBE INDUSTRIES, LTD. (JP) | 2019-10-01 | — | — | US | disclosed |
| US-20170114043-A1 | N-SUBSTITUTED SULFONAMIDE COMPOUND AND METHOD FOR PRODUCING SAME | UBE INDUSTRIES, LTD. (JP) | 2017-04-27 | — | — | US | disclosed |
| EP-3156396-A1 | N-SUBSTITUTED SULFONAMIDE COMPOUND AND METHOD FOR PRODUCING SAME | UBE Industries, Ltd. (JP) | 2017-04-19 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114043-A1 | N-SUBSTITUTED SULFONAMIDE COMPOUND AND METHOD FOR PRODUCING SAME | STS, CA7, CA4 | CYP1A2 609/4885CYP2A6 492/4885KDM4E 1916/4885 |
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | NOTCH1, NOTCH2, HES1 | CYP1A2 2773/4885CYP2A6 3870/4885KDM4E 1654/4885 |
| US-10774072-B2 | Crystal of N-substituted sulfonamide compound | STS, SLC10A6, CA3 | CYP1A2 868/4885CYP2A6 845/4885KDM4E 2095/4885 |
| US-10428046-B2 | N-substituted sulfonamide compound and method for producing same | STS, CA7, CA4 | CYP1A2 609/4885CYP2A6 492/4885KDM4E 1916/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP1A2 659/4885CYP2A6 1119/4885KDM4E 4854/4885 |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MKI67, CCNI, KRAS | CYP1A2 2080/4885CYP2A6 3211/4885KDM4E 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.